Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded Healthcare sector company. As of October 15, 2026, SUPN trades at $40.10 with a market cap of $2.45B and a P/E ratio of -22.50. SUPN moved -0.20% today. Year to date, SUPN is -18.78%; over the trailing twelve months it is -18.37%. Its 52-week range spans $29.16 to $59.68. Analyst consensus is strong buy with an average price target of $64.67. Rallies surfaces SUPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest SUPN news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $40.10 |
| Market Cap | $2.45B |
| P/E Ratio | -22.50 |
| EPS | $-1.92 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.68 |
| 52-Week Low | $29.16 |
| Volume | 197 |
| Avg Volume | 0 |
| Revenue (TTM) | $830.44M |
| Net Income | $-109.89M |
| Gross Margin | 88.08% |
3 analysts cover SUPN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $64.67.